Oveporexton · Orzeyful

Small molecule

Also known as TAK-861

Approvedregulatory verdict

Evidence outlook

Approved: Narcolepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Narcolepsy
NCT07363720 · Takeda
2026-01-29 – 2026-12-17 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
What this study did
NCT06505031 · Takeda
2024-10-08 – 2025-06-04 · Narcolepsy Type 1
What this study did
NCT06470828 · Takeda
2024-07-02 – 2025-06-03 · Narcolepsy Type 1
What this study did
Phase 2/3 (1)
Narcolepsy
NCT05816382 · Takeda
2023-04-05 – 2028-02-28 · Narcolepsy Type 1
What this study did
Phase 2 (2)
Narcolepsy
NCT05687916 · Takeda
2023-01-09 – 2023-12-25 · Narcolepsy Type 2
What this study did
NCT05687903 · Takeda
2023-01-09 – 2023-12-14 · Narcolepsy Type 1
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Narcolepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Oveporexton (Orzeyful): this drugApprovedSmall moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav)ApprovedSmall moleculeGABA-B receptornot yet gradedNo reviewed efficacy summary in this indication
Modafinil (Provigil)ApprovedSmall moleculeSympathomimetic-like Agentnot yet gradedNo reviewed efficacy summary in this indication
Pitolisant (Wakix)ApprovedSmall moleculeHistamine H3 receptor (antagonist / inverse agonist)Reliable signal
NCT02611687: To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35)
Sodium OxybateApprovedSmall moleculeGABA-B receptorPartial signalFeatured results are non-efficacy only in this race
Solriamfetol (Sunosi)ApprovedSmall moleculeDopamine/norepinephrine transporterPartial signal
NCT02348632: Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results).
NCT02348593: Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label).
AlixorextonPhase 3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
ReboxetinePhase 3Small moleculenorepinephrine transporterPartial signal
NCT05113745: Primary endpoint, change in frequency of cataplexy attacks in the randomized withdrawal phase: statistically significant improvement vs placebo (Axsome, 2024-11-26).
CleminorextonPhase 2/3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
TAK-360Phase 2/3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Pitolisant GR
—(overall)
Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Orzeyful (Oveporexton) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3NarcolepsyActive not recruiting
Est. primary completion 2026-12-17 · NCT07363720 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 2/3NarcolepsyRecruiting
Est. primary completion 2028-02-28 · NCT05816382 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 August 2026ApprovalORZEYFUL approved in Japan for narcolepsy type 1
JP, MHLW · Source ↗
5 August 2026ApprovalFDA approves ORZEYFUL (oveporexton) for narcolepsy type 1
US, FDA · Source ↗
22 July 2026ApprovalORZEYFUL (oveporexton) approved in China for narcolepsy type 1
CN, NMPA · Source ↗
14 July 2025Topline resultPositive topline results from two Phase 3 studies (FirstLight and RadiantLight) of oveporexton in NT1